Navigation Links
Multimodal Treatment of Peritoneal Metastases Offers Hope for Many Patients With Colorectal Cancer

BERLIN, November 1, 2012 /PRNewswire/ --

8th World Congress on Peritoneal Surface Malignancies

At the 8th World Congress on Peritoneal Surface Malignancies held from October 30 to November 2 in Berlin, Germany, a paradigm shift was emphasized that offers hope to numerous cancer patients worldwide. So far patients with peritoneal metastases of solid tumors in the abdominal region were considered not to be candidates for curative treatment. These patients had an extremely poor prognosis and were treated solely with systemic chemotherapy within the framework of "best supportive care."

At the international congress definitive data was presented sharing that multimodal treatment of peritoneal metastases of colorectal cancer can be a promising approach and is associated with a five-year survival of up to 30-50%. Dr. Paul Sugarbaker (Washington, DC, USA), surgeon and congress president, is considered a pioneer of this approach which uses a combination of cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC) and subsequent systemic chemotherapy. With HIPEC the chemotherapeutic agent is distributed in the abdominal region at 42°C for about 60 to 90 minutes. "The residual tumor tissue is exposed to a multiple of the normal concentration of the cytotoxic agent that is administered during conventional chemotherapy," explained Sugarbaker. "This is why the method is successful. In selected patients it can double the survival time - and should therefore be considered as a therapeutic option within an individualized treatment approach".

The aspect of individualized treatment is important, because the method is suitable only for patients with isolated and limited peritoneal carcinomatosis without metastases outside the abdomen. "However, this group constitutes up to 15% of all patients with colorectal cancer after all," pointed out Dr. Prof. Pompiliu Piso (Regensburg, Germany), co-president of the congress. "In simple terms this means that in Germany, for example, where there are 70,000 new cases of colon cancer each year, the prognosis of around 10,000 patients could be substantially improved by the use of this method."

Further information

Press contact
Dr. Bettina Albers
Tel. + 49-174-2165629

SOURCE 8th World Congress on Peritoneal Surface Malignancies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
2. Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
3. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
4. Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
5. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
6. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
7. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
8. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
9. CTBE (Brazil) to Acquire Equipment for Biomass Pretreatment Research
10. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
11. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
Post Your Comments:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):